ClinicalTrials.gg
CompletedNCT01084551Updated Jun 5, 2014Results posted

Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

A Phase 3 interventional study of SPM 962 and SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-06-05.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
5th of 19
284 · median 130
Started
2010
the only one that year
Phase 3
10 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 9th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg during a 13-week dose-titration and maintenance period. This is a multi-center, randomized, placebo-controlled, double-blind, 3-armed parallel group comparison study.

Efficacy will be determined by investigating the superiority of SPM962 to placebo in terms of the primary efficacy variable, change in International Restless Legs Syndrome Rating Scale (IRLS) total score from baseline to the end of the dose-maintenance period.

03

Conditions studied

  • Idiopathic Restless Legs Syndrome
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients whose condition has been diagnosed as RLS by meeting all 4 of the International Restless legs Syndrome Study Group/ National Institute of Health (IRLSSG/NIH) criteria
  • Patients who meet any of the following criteria relating to RLS treatment:

    • Patients who have never received treatment for RLS
    • Patients who have received treatment for RLS in the past and responded to L-dopa or dopamine agonists (Response to other RLS medicines is irrelevant.)
  • Patients who have an IRLS total score of >=15 at baseline
  • Patients who experience symptoms in the evening or during the night on at least two days a week within 14 days prior to commencement of study treatment
  • Patients and their partners can practice at the end of follow-up observation period or by 1 week after the end of treatment

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously participated in a clinical trial of SPM962 and taken the product (IP)
  • Patients with secondary RLS induced by renal impairment (uremia), iron deficiency anemia, drugs, pregnancy, etc.
  • Patients who currently suffer, are at risk of developing, or have a history of sleep disorder such as sleep apnea syndrome, narcolepsy, and sleep attacks/sudden onset of sleep
  • Patients who have concomitant diseases or symptoms which may affect the symptoms of RLS, such as polyneuropathy (including diabetic neuropathy), akathisia, claudication, varicoses, muscle fasciculation, painful legs and moving toes syndrome, radiculopathy and folate deficiency
  • Patients who have other CNS diseases such as Parkinson's disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington's Chorea, amyotrophic lateral sclerosis, and Alzheimer's disease
  • Patients who have psychiatric conditions such as confusion, hallucination, delusion, and excitation, or patients who have abnormal behavior such as delirium, obsessive compulsive disorder, and impulse control disorder at the time of the screening test or baseline examination
  • Patients whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or patients who develop orthostatic hypotension at baseline
  • Patients who have a history of epilepsy, convulsion, etc
  • Patients who have complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris)
  • Patients with arrhythmia who have been taking Class 1a antiarrhythmic drugs (eg., quinidine, procainamide) or Class 3 antiarrhythmic drugs (eg., amiodarone, sotalol)
  • Patients who have a serious abnormality at the screening test and at the baseline examination

    • Patients who show exceeding 450 ms in both ECGs in the screening test
    • Patients who have an average QTc interval from the two ECGs in the baseline assessment that exceeds 470 ms (for females) or 450 ms (for males)
  • Patients with congenital long QT syndrome
  • Patients whose serum potassium level is \< 3.5mEq/L at the screening test
  • Patients whose total is >= 3.0mg/dL, or whose (GOT) and ALT(GPT) are equal or more than 2.5 times the reference range of the clinical site (or >= 100IU/L) at the screening test
  • Patients whose BUN level is >= 30mg/dL, or whose serum creatinine level is >= 2.0mg/dL at the screening test
  • Patients who have a history of allergy to topical agents such as transdermal patch
  • Patients who are pregnant or nursing or who wish to become pregnant during the study period
  • Patients who habitually drink alcohol or smoke excessively
  • Patients who engage in evening shift work or other such shift work, or whose work or circumstances makes it difficult to maintain a regular period of sleep
  • Patients who engage in hazardous work such as driving a vehicle, operating machinery, or working in a high location.
  • Patients with disease, chronic active hepatitis, or immune deficiency disorder
  • Patients who have a complication or history of malignant neoplastic disease, or received treatment for the disease within 12 months prior to the screening test
  • Patients who are unable to properly record information in a patient diary
  • Patients who received other IPs within 12 weeks prior to commencement of study treatment
  • Patients who have been judged by the investigator or the sub-investigator to be inappropriate for inclusion in the study for any other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    SPM 962 4.5

    started at 2.25 mg/day to 4.5 mg/day for 13 weeks

    Drug: SPM 962

  • Experimental
    SPM 962 6.75

    started at 2.25 mg/day to 6.75 mg/day for 13 weeks

    Drug: SPM 962

  • Placebo comparator
    placebo

    for 13 weeks

    Drug: Placebo of SPM 962

Interventions

  • once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks

  • once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks

  • DrugPlacebo of SPM 962

    once a daily transdermal administration for 13 weeks

06

What researchers measure

Primary outcomes

  1. International Restless Legs Syndrome Rating Scale (IRLS) Total Score

    Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

Secondary outcomes

  1. Clinical Global Impression (CGI) Improvement

    CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  2. Patient Global Impression (PGI) Improvement

    PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  3. The Pittsburgh Sleep Quality Index (PSQI)

    Change of PSQI from baseline to the end of dose-titration/dose-maintenance period. PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  4. Each Item of IRLS (10 Items)

    IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  5. Incidence of RLS Symptoms

    Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week\* 100%

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  6. Average Duration of RLS Symptoms

    Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)

  7. Incidence of RLS Symptoms in the Evening and Night

    Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation \* 100%.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  8. Average Duration of RLS Symptoms in the Evening and Night in a Week

    Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)

  9. Nocturnal Awakenings Due to RLS Symptoms in a Week

    Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation \* 100%.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)

  10. Average Sleep Time in a Week

    Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.

    Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)

07

Results

Posted Jun 5, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboSPM 962 4.5SPM 962 6.75
Started959594
Completed868186
Not completed9148
Withdrew: Adverse event294
Withdrew: Lack of efficacy201
Withdrew: Withdrawal by subject210
Withdrew: Protocol violation240
Withdrew: Lost to follow-up003
Withdrew: Physician decision100

Outcome measures

PrimaryInternational Restless Legs Syndrome Rating Scale (IRLS) Total Score

Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Mean · Scores on a scale
International Restless Legs Syndrome Rating Scale (IRLS) Total Score
Scores on a scalePlaceboSPM 962 4.5SPM 962 6.75
International Restless Legs Syndrome Rating Scale (IRLS) Total Score-11.6 ± 8.2-14.3 ± 8.9-14.6 ± 9.0
SecondaryClinical Global Impression (CGI) Improvement

CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Number · Percentage of Participants
Clinical Global Impression (CGI) Improvement
Percentage of ParticipantsPlaceboSPM 962 4.5SPM 962 6.75
Subjects with "much improved"24.225.829.0
Subjects with "very much improved"33.741.945.2
SecondaryPatient Global Impression (PGI) Improvement

PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Number · Percentage of Participants
Patient Global Impression (PGI) Improvement
Percentage of ParticipantsPlaceboSPM 962 4.5SPM 962 6.75
Subjects with "much improved"23.224.730.1
Subjects with "very much improved"38.948.450.5
SecondaryThe Pittsburgh Sleep Quality Index (PSQI)

Change of PSQI from baseline to the end of dose-titration/dose-maintenance period. PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Mean · Scores on a scale
The Pittsburgh Sleep Quality Index (PSQI)
Scores on a scalePlaceboSPM 962 4.5SPM 962 6.75
The Pittsburgh Sleep Quality Index (PSQI)-2.5 ± 2.4-3.1 ± 3.2-3.2 ± 3.3
SecondaryEach Item of IRLS (10 Items)

IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Number · percentage of participants
Each Item of IRLS (10 Items)
percentage of participantsPlaceboSPM 962 4.5SPM 962 6.75
-4 (RLS discomfort)1.12.26.4
-3 (RLS discomfort)11.617.212.8
-4 (need to move around due to RLS symptoms)2.12.27.4
-3 (need to move around due to RLS symptoms)11.625.818.1
-4 (discomfort relief by moving around)01.12.1
-3 (discomfort relief by moving around)10.520.428.7
-4 (severity of RLS as a whole)1.11.14.3
-3 (severity of RLS as a whole)6.312.912.8
-4 (RLS symptoms frequency)12.624.726.6
-3 (RLS symptoms frequency)12.69.711.7
-4 (average duration of RLS symptoms)1.12.22.1
-3 (average duration of RLS symptoms)6.310.89.6
-4 (severity of sleep disturbance)2.14.36.4
-3 (severity of sleep disturbance)16.816.121.3
-4 (tiredness or sleepiness during the day)02.22.1
-3 (tiredness or sleepiness during the day)8.411.88.5
-4 (severity of the impact on daily affairs)01.11.1
-3 (severity of the impact on daily affairs)8.411.84.3
-4 (severity of mood disturbance)1.14.31.1
-3 (severity of mood disturbance)8.410.812.8
SecondaryIncidence of RLS Symptoms

Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week\* 100%

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Mean · percentage of days with RLS symptom
Incidence of RLS Symptoms
percentage of days with RLS symptomPlaceboSPM 962 4.5SPM 962 6.75
Baseline85.7 ± 20.885.4 ± 20.583.2 ± 22.2
Week 1348.7 ± 40.935.8 ± 38.636.8 ± 38.8
SecondaryAverage Duration of RLS Symptoms

Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
Reported as:
Mean · Hours
Average Duration of RLS Symptoms
HoursPlaceboSPM 962 4.5SPM 962 6.75
Average Duration of RLS Symptoms-3.1 ± 4.7-3.7 ± 4.6-4.3 ± 4.4
SecondaryIncidence of RLS Symptoms in the Evening and Night

Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation \* 100%.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Mean · percentage of days/week with symptoms
Incidence of RLS Symptoms in the Evening and Night
percentage of days/week with symptomsPlaceboSPM 962 4.5SPM 962 6.75
Baseline80.6 ± 24.283.3 ± 20.879.5 ± 24.2
Week 1345.4 ± 41.034.6 ± 38.231.8 ± 37.7
SecondaryAverage Duration of RLS Symptoms in the Evening and Night in a Week

Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
Reported as:
Mean · Hours
Average Duration of RLS Symptoms in the Evening and Night in a Week
HoursPlaceboSPM 962 4.5SPM 962 6.75
Average Duration of RLS Symptoms in the Evening and Night in a Week-1.3 ± 3.1-1.8 ± 2.5-1.5 ± 2.3
SecondaryNocturnal Awakenings Due to RLS Symptoms in a Week

Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation \* 100%.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (week 13)
Reported as:
Mean · percentage of days/week with awakening
Nocturnal Awakenings Due to RLS Symptoms in a Week
percentage of days/week with awakeningPlaceboSPM 962 4.5SPM 962 6.75
Baseline33.5 ± 35.922.6 ± 31.328.3 ± 34.3
Week 1315.6 ± 31.77.7 ± 20.57.5 ± 19.5
SecondaryAverage Sleep Time in a Week

Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.

Time frame:
Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
Reported as:
Mean · Hours
Average Sleep Time in a Week
HoursPlaceboSPM 962 4.5SPM 962 6.75
Average Sleep Time in a Week0.4 ± 0.80.5 ± 1.10.4 ± 1.1

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/95 (2.1%)32/95 (33.7%)
SPM 962 4.5—0/95 (0%)72/95 (75.8%)
SPM 962 6.75—1/94 (1.1%)77/94 (81.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboSPM 962 4.5SPM 962 6.75
ContusionInjury, poisoning and procedural complications0/950/951/94
Traffic AccidentInjury, poisoning and procedural complications0/950/951/94
Lacunar InfarctionNervous system disorders1/950/950/94
VIIth Nerve ParalysisNervous system disorders1/950/950/94
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboSPM 962 4.5SPM 962 6.75
Application Site ReactionGeneral disorders7/9540/9547/94
NauseaGastrointestinal disorders9/9532/9541/94
NasopharyngitisInfections and infestations12/9512/9516/94
SomnolencePsychiatric disorders2/9510/9514/94
VomitingGastrointestinal disorders1/954/9510/94
Abdominal DiscomfortGastrointestinal disorders3/950/9510/94
HeadacheNervous system disorders0/955/952/94
Upper Respiratory Tract InflammationRespiratory, thoracic and mediastinal disorders1/953/954/94
Ventricular ExtrasystolesCardiac disorders0/950/953/94
ConstipationGastrointestinal disorders0/953/953/94

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboSPM 962 4.5SPM 962 6.75Total
Mean53.4 ± 15.350.7 ± 13.350.9 ± 13.751.7 ± 14.1
Age, Categorical
Age, Categorical(Participants)PlaceboSPM 962 4.5SPM 962 6.75Total
<=18 years0000
Between 18 and 65 years657777219
>=65 years30181765
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSPM 962 4.5SPM 962 6.75Total
Female545446154
Male414148130
Region of Enrollment
Region of Enrollment(participants)PlaceboSPM 962 4.5SPM 962 6.75Total
Japan959594284
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kansai Region, Japan
  • Kanto Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

References and documents

Publications

  • Inoue Y, Shimizu T, Hirata K, Uchimura N, Ishigooka J, Oka Y, Ikeda J, Tomida T, Hattori N; Rotigotine Trial Group. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med. 2013 Nov;14(11):1085-91. doi: 10.1016/j.sleep.2013.07.007. Epub 2013 Aug 21. PubMed 24055212 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 10, 2010
Start
Feb 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Jun 5, 2014
Last update
Jun 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01084551
Responsible party
Sponsor
First posted
Mar 10, 2010
Start date
Feb 2010
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Jun 5, 2014
Last update
Jun 5, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion